Amdocs disclosed a contractual dispute with T-Mobile involving alleged breaches and potential arbitration, alongside a forecasted revenue drop of up to 17.9% and earnings decline of up to 30% for fiscal 2027. This news led to a sharp 29% intraday share price fall on November 4, 2026. The company cited the dispute, reduced spending by T-Mobile, and completion of a customer integration project as reasons for the weaker outlook. Investors affected by losses are being invited to join a securities investigation by Kehoe Law Firm.
Amdocs faces a forecasted revenue drop of up to 17.9% and earnings decline of up to 30% for fiscal 2027 amid a dispute with T-Mobile. For readers following Technology-sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 21:31 WIB: out of 150 priced US stocks, 94 rose and 55 fell. Notable movers include CORZ at USD 13.45 with a 5.55% decline and 100% buy order activity, STX at USD 573.07 down 5.49% with 83% sell orders, and CDW at USD 157.94 up 5.46% with a typical hold time of 60 days.
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
A growing town replaced its inefficient IT request process of spreadsheets and emails with a centralized Microsoft Power Apps hub developed by eSoftware Associates. This hub integrates project intake, risk assessment, and PMO scoring into one platfor...
No7 Software has enhanced its Anchor Loyalty & Rewards app by integrating Shopify POS, allowing merchants to run a unified loyalty program across online stores and physical shops. Customers now maintain a single points balance, tier status, and refer...
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
